BRWM
ENTA icon

B. Riley Wealth Management’s Enanta Pharmaceuticals ENTA Stock Holding History

B. Riley Wealth Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,987
Closed -$128K – 1087
2014
Q2 		$128K Sell
2,987
-55
-2% -$2.1K 0.08% 295
2014
Q1 		$122K Buy
+3,042
New +$110K 0.09% 272

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

B. Riley Wealth Management's ENTA Position: Q3 2014 in Review

B. Riley Wealth Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2014, closing a stake of 2,987 shares — an estimated $128K sold.

B. Riley Wealth Management first reported a position in ENTA in Q1 2014 and held it in 2 quarters. The position peaked at $128K in Q2 2014. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2014.

  • B. Riley Wealth Management reported no remaining Enanta Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • B. Riley Wealth Management sold 2,987 Enanta Pharmaceuticals shares in Q3 2014, an estimated $128K.
  • B. Riley Wealth Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • B. Riley Wealth Management's Enanta Pharmaceuticals position peaked at $128K in Q2 2014.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2014.

Based on B. Riley Wealth Management's 13F filing for Q3 2014, filed 3 Oct 2014.